Sharescart Research Club logo
Apollo Green 60 (-3.2%)Axles India 525 (6.1%)Bira 108 (0%)CIAL 438 (0%)CSK 268 (8.1%)ESDS Software 448 (-3.7%)Garuda Aerospace 485 (-2%)GFCL EV 42 (0%)HDFC Securities 8950 (-0.6%)Hella Infra 110000 (-2.2%)Hero Fincorp 1075 (2.4%)HPX India 28 (7.7%)Incred Holdings 152 (2.7%)India Carbon 895 (0%)Indian Potash 2850 (1.8%)Inox Clean 725 (-8.8%)Insolare Energy 185 (0%)Matrix Gas 16 (0%)Motilal Oswal 12.95 (17.7%)MSEI 6.25 (-5.3%)NCDEX 398 (-1.7%)NeRL 58 (0%)NSE 1965 (4.2%)Onix Renewable 66 (13.8%)Orbis Financial 408 (0.7%)OYO 24 (0%)Pharmeasy 6.25 (-3.8%)Polymatech Electronics 62 (-3.1%)RRP S4E 168 (-10.6%)SBI Mutual 775 (0%)Ticker Ltd 32 (0%)Zepto 49 (-9.3%)

15 Days Price Change

Aptus Pharma IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds
Profile
Issue Size 9.32 Cr
Profile
Price Range 65  to  70 per share
Profile
Min Investment ₹70
Profile
Lot Size 1
Profile
Face Value ₹10
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Our Company is engaged in the business of marketing, and distribution of finished pharmaceutical formulations. While the Company does not own any manufacturing facilities, it operates through a contract manufacturing model. We do not own any manufacturing plants but has entered into contract manufacturing agreement with seven manufacturing units. under various arrangements. Of these, we have formal loan and license agreements in place with two manufacturing units. The remaining production is carried out through informal arrangements with Other manufacturers, based on purchase orders (PO). We provide a diverse range of pharmaceutical products catering to various therapeutic categories including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, anti-diabetic, lipid-lowering, and general wellness products. These are offered across a variety of dosage forms, such as tablets, capsules, softgels, syrups, suspensions, injections, ointments, creams, balms, drops, lotions, vials, powders, gels, and sachets. Read More

Basic Info

Face Value 10 per share

Price 65  to  70 per share

P/E (x) 10.9

Sales( Cr.) 25

PAT( Cr.) 3

EPS 6.4

Draft Prospectus

Exchange BSE-SME

Promoter

Company Promoters

Tejash Maheshchandra Hathi Milly Chetan Lalseta Riddhish Natwarlal Tanna Kapilbhai Hasmukhbhai Chandarana Ghanshyam Vinubhai Pansuriya Chatrabhuj Vallabhbhai Butani Gaurang Rameshchandra Thakker Kripaliben Mayank Thakker Kunjal Piyushbhai Unadkat

Pre Issue Share Holding 100%

Post Issue Share Holding 72.88%

Listing Details:

Listing Price: 80.8

Listing Gain: 13.37%

Current Price: 395.1

Gain On Issue: 395.1 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Sep 23, 2025
Closing Date Sep 25, 2025
Allotment Sep 26, 2025
Refund Sep 29, 2025
Delivery of Shares Sep 29, 2025
Listing Date Sep 30, 2025

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 4000 280,000
Retail (Max) -- -- --
S-HNI (Min) 1 4000 280,000
S-HNI (Max) 3 12000 840,000
B-HNI (Min) 4 16000 1,120,000

Objective of the Issue

1. Capital Expenditure for Office Premises with furniture and Industrial Racks.2. Working Capital3. General Corporate Purpose

Issue

Category Nos Bid Bid (x)
QIB 352000 436000 1.2x
NII 360000 7742000 21.5x
Retail 620000 19520000 31.5x
EMP 0 0 0x
Total 1332000 27698000 20.8x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Aptus Pharma Profit & Loss

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 14 18 25
Other Income 0 0 0
Total Income 14 18 25
Total Expenditure 13 16 20
Operating Profit 1 2 5
Interest 0 0 0
Depreciation 0 0 0
Exceptional Income / Expenses 0 0 0
Profit Before Tax 0 1 4
Provision for Tax 0 0 1
Profit After Tax 0 1 3
Adjustments 0 0 0
Profit After Adjustments 0 1 3
Adjusted Earnings Per Share 1.3 5.3 1.2

Aptus Pharma Balance Sheet

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 1 2 7
Minority's Interest 0 0 0
Borrowings 2 4 3
Other Non-Current Liabilities 0 0 0
Total Current Liabilities 3 4 12
Total Liabilities 6 10 22
Fixed Assets 1 1 1
Other Non-Current Assets 0 1 1
Total Current Assets 6 8 20
Total Assets 6 10 22

Aptus Pharma Cash Flow

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 1 1
Cash Flow from Operating Activities -0 -2 -2
Cash Flow from Investing Activities -0 -0 -1
Cash Flow from Financing Activities 1 3 7
Net Cash Inflow / Outflow 0 0 4
Closing Cash & Cash Equivalent 1 1 5

Aptus Pharma Ratios

# Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 1.3 5.32 1.24
CEPS(Rs) 2.5 6.75 1.35
DPS(Rs) 0 0 0
Book NAV/Share(Rs) 6.46 11.78 2.79
Core EBITDA Margin(%) 4.4 8.61 19.44
EBIT Margin(%) 3.12 7.55 18.69
Pre Tax Margin(%) 2.1 6.22 16.82
PAT Margin (%) 1.38 4.44 12.43
Cash Profit Margin (%) 2.67 5.64 13.49
ROA(%) 3.14 9.88 19.48
ROE(%) 20.06 58.36 70.99
ROCE(%) 13.79 26.47 38.22
Receivable days 62.23 58.41 65.8
Inventory Days 59.65 58.13 76.71
Payable days 104.57 72.69 53.78
PER(x) 0 0 0
Price/Book(x) 0 0 0
Dividend Yield(%) 0 0 0
EV/Net Sales(x) 0.14 0.26 0.41
EV/Core EBITDA(x) 3.19 2.99 2.06
Net Sales Growth(%) 0 28.49 37.52
EBIT Growth(%) 0 209.6 243.52
PAT Growth(%) 0 310.76 288.37
EPS Growth(%) 0 310.76 -76.7
Debt/Equity(x) 2.28 3 1.49
Current Ratio(x) 1.81 2.01 1.63
Quick Ratio(x) 1.07 1.18 1.05
Interest Cover(x) 3.06 5.67 9.97
Total Debt/Mcap(x) 0 0 0

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 39% 0% 0% 0%
Operating Profit CAGR 150% 0% 0% 0%
PAT CAGR 200% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR NA% NA% NA% NA%
ROE Average 71% 50% 50% 50%
ROCE Average 38% 26% 26% 26%

Company Contact Information

Aptus Pharma Ltd.

Mohini Hardik Gandhi

+91 76004 27827

info@aptuspharma.com

IPO Lead Manager(s)

Aptus Pharma Ltd.

Interactive Financial Services Ltd.

Registrar Info

Aptus Pharma Ltd.

Bigshare Services Pvt Ltd

Office No S6-2, 6th Floor, Pinnacle Business Park,ext to Ahura Centre, Mahakali Caves Road, Andheri (East) Mumbai - 400093 (old address - Bharat Tin Works building, 1st floor, Opp. Vasant Oasis, Andheri East Mumbai - 400 059 Tel: + 91 21 626 38200 Fax:

91-022-62638200

91-022-62638299

Investor@bigshareonline.com

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp